Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Melanoma 70 Neoplasms 47 Carcinoma, Non-Small-Cell Lung 26 Colorectal Neoplasms 20 Neoplasm Metastasis 15 Multiple Myeloma 14 Thyroid Neoplasms 12 Glioma 12 Pancreatic Neoplasms 11 Hematologic Neoplasms 10 Thyroid Carcinoma, Anaplastic 9 Brain Neoplasms 8 Lung Neoplasms 7 Triple Negative Breast Neoplasms 5 Rectal Neoplasms 5 Neurofibromatosis 1 5 Lymphoma 5 Leukemia, Myeloid, Acute 5 Colonic Neoplasms 5 Breast Neoplasms 5 Astrocytoma 5 Thyroid Cancer, Papillary 4 Prostatic Neoplasms 4 Neurofibroma, Plexiform 4 Glioblastoma 4 Cholangiocarcinoma 4 Biliary Tract Neoplasms 4 Uveal Melanoma 3 Skin Neoplasms 3 Recurrence 3

Interventions

trametinib 1 dabrafenib 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Rare Malignant Neoplasm × trametinib × Clear all

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡